. They are suggested to be a heterogeneous population involved in resorbing diverse skeletal surfaces such as bone, cartilage and dentine 8, 9 . However, the existence of cartilage-resorbing osteoclasts, sometimes termed chondroclasts, has been debated for a long time because of the lack of in vivo or in situ characterization.
The elongation of endochondral bones occurs at the growth plate cartilage 1, 10 where proliferating and differentiating chondrocytes release vascular endothelial growth factor (VEGF) to attract blood vessels 11 . Blood vessel growth is associated with bone formation during endochondral ossification 12, 13 . A specialized blood vessel subtype, termed type H, expressing high levels of the endothelial markers CD31 and endomucin couples angiogenesis and osteogenesis 14, 15 . Age-associated decline in bone mass is associated with the loss of these specialized blood vessel capillaries 14, 16 . In this study, we identify a distinct subset of osteoclasts to be closely associated with type H capillaries and which is found to not spread over skeletal surfaces. Specific association with type H capillaries means that these osteoclasts populate bone during formation rather than resorption. We further demonstrate functions of these osteoclasts and blood vessels in removing cartilage matrix that have implications for improving healing of bone fractures and provide insight into the way pathologies such as arthritis and cancer degrade the skeletal matrix.
Results

Distinct osteoclast subtypes in bone.
To understand cartilage replacement at the growth plate, we first characterized osteoclast subtypes involved in cartilage resorption. We performed high-resolution three-dimensional confocal immunofluorescence imaging with several in vitro-defined osteoclast markers along with tartrateresistant alkaline phosphatase (TRAP) to gain detailed insight into the distribution of osteoclasts in bone. TRAP-and integrin-beta-3 (Itgb3)-expressing osteoclasts were predominantly localized in the metaphysis (Fig. 1a,b and Supplementary Fig. 1a,b) . The expression of another osteoclast marker, V-type proton pump-3 (Vpp3), specifically identified osteoclasts and was undetectable in circulating cells in the bone marrow cavity ( Fig. 1c and Supplementary Fig. 1c ).
The distribution of Vpp3
+ osteoclasts in the metaphysis was similar to TRAP + or Itgb3 + osteoclasts. We also visualized osteoclasts using inducible Csf1r
Mer-iCre-Mer (ref.
17
) Rosa26-tdTomato 18 double-transgenic mice ( Supplementary Fig. 1d ). Both of the strategies uncovered distinct localization of osteoclasts in bone. In the metaphysis, osteoclasts were preferentially localized at the bone/cartilage interface (proximal) and on the trabecular bone surface (distal).
Comparing the phenotypes of these osteoclasts demonstrated that distal osteoclasts were large (60-100 μm), multinucleated (~4-6) cells displaying characteristics of previously defined bone-resorbing osteoclasts, in comparison to relatively smaller (15-20 μm), 1-2-nucleated proximal osteoclasts (Fig. 1d) . Apart from osteoclast marker expression (Fig. 1a-c and Supplementary Fig. 1e ), the size and shape of these cells suggested that proximal osteoclasts were not circulating macrophages/monocytes.
Cathepsin K (Ctsk) expression could demarcate these osteoclast subtypes, as proximal osteoclasts were a Ctsk low population 
*
Growth plate cartilage contributes to the generation of a large variety of shapes and sizes of skeletal elements in the mammalian system. The removal of cartilage and how this process regulates bone shape are not well understood. Here we identify a non-bone-resorbing osteoclast subtype termed vessel-associated osteoclast (VAO). Endothelial cells at the bone/cartilage interface support VAOs through a RANKL-RANK signalling mechanism. In contrast to classical bone-associated osteoclasts, VAOs are dispensable for cartilage resorption and regulate anastomoses of type H vessels. Remarkably, proteinases including matrix metalloproteinase-9 (Mmp9) released from endothelial cells, not osteoclasts, are essential for resorbing cartilage to lead directional bone growth. Importantly, disrupting the orientation of angiogenic blood vessels by misdirecting them results in contorted bone shape. This study identifies proteolytic functions of endothelial cells in cartilage and provides a framework to explore tissue-lytic features of blood vessels in fracture healing, arthritis and cancer.
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NATuRE CELL BIOLOGy compared to the high-expressing distal osteoclasts ( Supplementary  Fig. 1e ). Interestingly, proximal osteoclasts were closely associated with type H vessels, which play an important role in developmental and regenerative osteogenesis [14] [15] [16] rather than skeletal surfaces. Specifically, they interacted with bulge and arch structures 16 of type H capillaries (Fig. 1e,f) while distal osteoclasts were stretched along bone surfaces. They did not express pro-angiogenic macrophage markers 19 such as Tie2 and Nrp1 ( Supplementary Fig. 1f,g ). Distal osteoclasts (~60%) on bone surfaces outnumbered vesselassociated proximal osteoclasts (~40%) in 4-week-old mouse tibia ( Supplementary Fig. 1h ). On the basis of these findings, we propose the following terminology: vessel-associated osteoclasts (VAO) for the proximal osteoclasts and bone-associated osteoclasts (BAO) for the distal osteoclasts in the metaphysis (Fig. 1g) .
Characterization of osteoclast subsets. Macrophages migrate from fetal liver to various tissues and organs during early development to form tissue-specific resident macrophages 20 . The origin of VAOs and BAOs was investigated by genetically pulse-chasing fetal liver macrophages using Csf1r
Mer-iCre-Mer , Rosa26-tdTomato double-transgenic mice. After a single tamoxifen injection at embryonic day 12.5 (E12.5), bones were analysed on E17.5, postnatal day 3 (P3), P14 and P28. Pulse-chasing fetal liver macrophages showed that both osteoclast subtypes were derived from fetal liver macrophages (Fig. 2a) . Similarly, we performed fate-mapping in early postnatal bones by pulse-labelling of cells at P10. This labelled a few macrophages when observed at 6 and 12 hpi (hours post injection) but both VAOs and BAOs were not labelled. Despite weak labelling at 24 hpi, both osteoclast subtypes were labelled at 24, 48 and 120 hpi ( Supplementary Fig. 1i ). To understand the relationship further, we labelled phagocytic cells by injecting liposome-encapsulated DiI dye. In 6 hpi bones, liposome-encapsulated DiI dye was detected primarily in diaphyseal macrophages and a very few cells in the metaphysis. Labelling of both VAOs and BAOs at 24 hpi in the metaphysis established the concurrent generation of both the osteoclast subsets from macrophages ( Supplementary Fig. 1j ). Labelling with 5-ethynyl-2′-deoxyuridine (EdU) revealed the non-proliferative nature of the osteoclast subtypes (Fig. 2b) . Remarkably, transplantation of VAO subsets into sub-lethally irradiated mice resulted in the formation of both VAOs and BAOs, indicating the potential + cells in relation to the blood vessels in the metaphysis (mp, blue box) and in the diaphysis (dp, yellow box). gp, growth plate; cb, compact bone. Scale bars, 500 μm (left), 50 μm (top right) and 70 μm (bottom right). b, Maximum-intensity projection of TRAP (green)-expressing cells along with endomucinstained blood vessels (Emcn, red) in the tibial metaphysis of a three-week-old mouse from three independent experiments. Scale bar, 50 μm. c, Confocal images showing the distribution of osteoclasts and blood vessels in the tibial metaphysis of a three-week-old mouse from four independent experiments. Vpp3 (green) and endomucin (Emcn, red) staining identifies osteoclasts and blood vessels, respectively. The blue arrowhead indicates proximal osteoclasts, and the white arrowhead indicates distal osteoclasts. Scale bar, 50 μm. d, Top: representative images showing proximal and distal osteoclasts immunostained with Vpp3 (green). Endomucin (Emcn, red) marks blood vessels, and DAPI is a nuclear counterstain. Scale bars, 20 μm. Bottom: quantification of the size and number of nuclei present in osteoclast subtypes localized in the proximal and distal region of the tibial metaphysis. The data represent mean ± s.e.m. The P values were calculated using two-tailed unpaired t-tests. The data points were pooled across multiple bone samples; n = 27 and n = 28 for osteoclast size and nuclei quantification, respectively. e, Confocal images showing the localization of proximal (left) and distal (middle) osteoclasts (Vpp3, green) in the metaphysis with respect to blood vessels (Emcn, red) from four independent experiments. Proximal osteoclasts are largely in close contact with blood vessels (blue arrows), whereas the majority of distal osteoclasts are not (white arrows). Right: an optical section of a confocal z-stack showing close association of blood vessels and osteoclasts in all three planes. Nuclei are labelled with DAPI. Scale bars, 20 μm. f, A transverse section of tibial metaphysis showing localization of blood vessels (Emcn, red) and osteoclasts (Vpp3, green) from three independent experiments. Blue and white arrows indicate blood vessel association of proximal and distal osteoclasts, respectively. Nuclei are labelled with DAPI. Scale bar, 50 μm. g, Schematic representation of osteoclast distribution in the bone metaphysis.
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Tamoxifen at E12. Mer-iCre-Mer and R26-tdTomato mice. Tamoxifen was injected at E12.5, and tdTomato expression was traced at E17.5, P3, P14 and P28 in three independent experiments. Vessels: CD31, red; osteoclasts: Itgb3, green; nucleus: DAPI, blue. Scale bars, 50 μm (E17.5, P14 and P28) and 100 μm (P3). Yellow arrowheads indicate Itgb3 (green) expression in Tomato + (magenta) osteoclasts. b, EdU labelling (magenta) in P14 mouse tibia from three independent experiments showing that both osteoclast subtypes (Itgb3, green) were not proliferating. DAPI (blue) stains nuclei. Scale bar, 50 μm. c, The sorted tomato + VAO subset was transplanted into irradiated recipients. Transplanted VAOs occupied bone surface in addition to blood vessels in three independent experiments. Scale bars, 50 μm. d, Representative flow cytometry plots showing the sorting profile used to separate VAOs and BAOs in ten independent experiments. RANK + cells with two nuclei (VAO) and greater than four nuclei (BAO) are sorted for gene expression analysis. e, RANK-and Vybrant-stained cells were imaged after sorting in three independent experiments to ensure purity. Scale bars, 20 μm. f, Left: a heat map showing RNA-seq expression levels of differentially expressed genes between VAO and BAO (FDR-adjusted P value cutoff < 0.05 with coding biotype). The colour code indicates the normalized log 2 -transformed counts per million reads with upregulated (red) and downregulated (blue) genes. Right: a volcano plot showing differentially expressed genes comparing BAO with VAO. Differentially expressed genes were calculated using a negative binomial Wald function, and P values were adjusted using the Benjamini-Hochberg method. Cells sorted from five independent experiments were pooled into two samples for RNA-seq. g, Cathepsin K transcripts (Ctsk) in RNA-sequenced samples of VAO and BAO subsets using n = 2 samples pooled from 5 independent experiments. RPKM, reads per kilobase per million mapped reads. The data represent mean values. h, Purified VAO and BAO subsets were subjected to quantitative PCR analysis for validating selected genes to confirm their expression pattern across independent experiments. The data represent mean ± s.d. The P values were calculated using two-tailed unpaired t-tests; Welch's correction was performed in sets with unequal sample numbers; n numbers represent biological replicates, pooled from eight experiments, and are indicated as data points in the graph. The source data are available in Supplementary Table 2 .
Articles NATuRE CELL BIOLOGy of the VAO subset to form BAOs (Fig. 2c) . BAOs did not survive the transplantation assay.
To gain insight into their molecular properties, RANK + total osteoclasts in bone were sorted by flow cytometry into VAOs (two nuclei) and BAOs (greater than four nuclei) on the basis of the number of nuclei (Fig. 2d,e and Supplementary Fig. 1k ). The purified osteoclast subsets were subjected to RNA-sequencing (RNA-seq) analysis. Both subtypes displayed distinct expression profiles, suggesting the independent nature of these osteoclasts. Differential gene expression analysis identified 950 genes with false discovery rate (FDR)-adjusted P value < 0.05 ( Fig. 2f and Supplementary Table 1 ). Consistent with the immunostaining results, Ctsk transcript levels were reduced in VAOs compared to BAOs (Fig. 2g) . We further subjected freshly purified osteoclasts to quantitative PCR with reverse transcription for a panel of differentially regulated genes and validated the RNA-seq results to confirm the distinct expression profiles of the osteoclast subsets (Fig. 2h) .
These observations established spatial and phenotypic heterogeneity in osteoclasts of long bones, which also applied to other skeletal structures in mice such as vertebra and sternum. The absence of VAO subsets in calvarium and compact bone indicated their specificity to endochondral ossification (Supplementary Fig. 2a-d ).
Bone endothelium supports VAO subtype. Bone remodels continuously and shows remarkable changes with age. We analysed osteoclast distribution with age-related changes in bone. Randomly distributed osteoclasts in early fetal bones showed selective positioning in postnatal bones with the alignment of type H and type L capillaries (Fig. 3a) . Quantification of total osteoclasts showed remarkable decline in osteoclast population in bones of ageing mice ( Fig. 3b ) and this decrease correlated with the age-dependent reduction in type H capillaries 14, 16 . VAOs were predominant in early developing bones while BAOs were the major subtype occupying ageing bones ( Supplementary Fig. 2e ). The stage-specific distribution of osteoclast subtypes indicated the prevalence of VAOs during developmental bone formation and BAOs during age-related bone loss.
The developmental association of VAOs with type H capillaries and their age-dependent reduction intrigued us to investigate their interaction in regenerative conditions. Exposure to irradiation injury led to a significant increase in VAO number (Fig. 3c ) coinciding with the increase in type H vessels 14 . We first reduced type H numbers pharmacologically using SU5416, an anti-angiogenic drug inhibiting VEGF receptor-2 21 . Systemic SU5416 treatment led to a decline in the VAO subset ( Supplementary Fig. 2f-h ). We also manipulated type H endothelial cells (ECs) genetically by targeting endothelial Notch signalling as described earlier 15 . This involves deletion of Delta-like ligand 4 (Dll4) and F-box and WD repeat domain containing 7 (Fbxw7) in ECs using Cdh5(PAC)-CreERT2 mice. Tamoxifen-inducible Cdh5(PAC)-CreERT2 14-16,22-24 specifically targets ECs in postnatal mouse bones ( Supplementary Fig. 2i ,j). Genetic reduction of type H ECs (Dll4 iΔEC ) led to a decline in the VAO subset ( Supplementary Fig. 3a) . Conversely, promotion of type H ECs (Fbxw7 iΔEC ) increased the VAO number ( Supplementary  Fig. 3b ). Endothelial deletion of von Hippel-Lindau tumour suppressor (Vhl) was earlier demonstrated to promote type H ECs 14, 23 . We reactivated type H ECs in aged mice by inducible endothelial specific Vhl deletion (Vhl iΔEC ), which led to the reappearance of VAOs in aged tibia ( Supplementary Fig. 3c ). This again established the importance of type H in regulating the VAO subset. Remarkably, both Dll4 iΔEC and SU5416-treated bones showed a dramatic increase in growth plate size in comparison to the respective controls (Fig. 3d ,e and Supplementary Fig. 4a,b) . We found accumulation of apoptotic cells in these growth plates, and expression of collagen-X and MMP13 in the hypertrophic zone ( Supplementary Fig. 4a-f ). This suggested defective replacement of chondrocytes and matrices in these animals.
Molecular interaction between VAOs and type H ECs.
To gain molecular insight into the association of VAOs with type H, we FACS-sorted type H and type L ECs, and analysed transcripts for important factors with known roles in osteoclast generation. Transcripts of important osteoclastogenic factors such as Csf1, Il1a and Tnfsf11a were highly expressed in type H compared to type L ECs (Fig. 3f ). Tnfsf11a (RANKL) serves as a ligand to signal RANK-expressing preosteoclasts in mediating osteoclast differentiation and activation 8, 25, 26 . High expression of Tnfsf11a in type H ECs argues for the possible involvement of RANKL-RANK signalling between type H ECs and VAOs. To investigate this, inducible EC-specific loss-of-function mice were generated using loxP-flanked Rankl alleles (Rankl lox/lox ) 27 and Cdh5(PAC)-CreERT2 transgenics. Following tamoxifen administration from P10 to P14, analysis of Rankl iΔEC mutants at P28 demonstrated reduction of Tnfsf11 transcripts specifically in ECs ( Supplementary Fig. 4g ). Endothelialspecific loss of Tnfsf11a (Rankl iΔEC ) reduced the VAO subset in bones along with a decrease in total osteoclasts number (Fig. 3g,h ). These mutants showed an increase in trabecular bone, while type H ECs were unaltered (Supplementary Fig. 5a-d) . To understand the osteoclast phenotype, we injected DiI-labelled liposomes to visualize localization of new phagocytic cells near mutated vessels. The specific absence of DiI-labelled phagocytes near type H vessels but unaffected bone surface suggested an unsuitable microenvironment provided by Rankl iΔEC endothelium ( Supplementary Fig. 5e ). This established the importance of Rankl in type H ECs to regulate VAO number. Remarkably, the growth plates of Rankl iΔEC mutants showed unaltered collagen-X and MMP13 expression, and apoptotic cells in the hypertrophic zone ( Fig. 3i and Supplementary Fig. 5f ).
VAOs are dispensable for growth plate resorption. The reduced osteoclast number, and their unaltered growth plates in Rankl iΔEC mutants prompted us to investigate the cartilage-resorptive function of osteoclasts by depleting osteoclasts genetically and pharmacologically. Bisphosphonates, a class of anti-resorptive drugs, function mainly by inhibiting osteoclasts 28, 29 . Administration of alendronate (1 mg kg −1 weight of mouse) twice a week for 4 weeks led to increased bone mass and reduced osteoclast number without affecting growth plate size (Fig. 4a,b and Supplementary  Fig. 6a,b) . The expression levels of the matrix protein and collagen-X and the number of apoptotic cells in the hypertrophic zone of alendronate-treated mice were similar to control animals ( Fig.  4c and Supplementary Fig. 6c ). We also analysed bones of mice showing severe osteopetrotic (op/op) mutation, which display defective osteoclasts, macrophages and monocytes 30, 31 . Despite having impaired osteoclast functions, growth plates of 21-dayold op/op mice remained unaffected (Fig. 4d) . Thus, these results indicated that defective osteoclast function did not affect cartilage resorption in bones.
To understand VAO functions, we targeted the VAO subtype specifically by short-term bisphosphonate treatment without altering the BAO subset. This VAO depletion could be maintained for seven days with intermittent bisphosphonate administration for three days ( Fig. 4e and Supplementary Fig. 6d) . The elongated type H capillaries in treated bones showed a significant decrease in arch structures in the vascular front (Fig. 4e,f) . Arch structures in type H capillaries are formed by anastomoses of bulges in the leading front 16 . The reduction in arch structures on VAO depletion suggested the involvement of VAOs in anastomosis of type H bulges. As the formation of bulges and arches is apparent in juvenile bones 16 , we depleted VAOs in two-week-old mice to investigate the formation of these angiogenic structures on blood vessels. We used liposome-encapsulated bisphosphonates (LEBs) to target osteoclasts and macrophages specifically. As was found for alendronate, short-term administration of LEB caused specific depletion of the VAO subset (Fig. 4g) . VAO depletion Articles NATuRE CELL BIOLOGy resulted in disturbed symmetry at the bone/cartilage interface. The absence of anastomoses led to unequal invasion of blood vessels with some individual blood vessels elongating more into the growth plate cartilage while some lagged behind (Fig. 4h) , resulting in the formation of a disturbed epiphysis line. Thus, VAOs play a role in maintaining the boundary of the The P values were calculated using two-tailed unpaired t-tests. f, Quantitative PCR analysis of pro-osteoclastogenic factors expressed on sorted bone ECs (type H and type L). Relative fold expression in type H ECs is calculated compared to type L. Transcript expression for each gene was normalized to β-actin levels. The data represent mean ± s.d. The P values were calculated using two-tailed unpaired t-tests; n numbers represent biological replicates, pooled from four experiments, and are indicated as data points in the graph. The source data are available in Supplementary Table 2 . The P values were calculated using two-tailed unpaired t-tests. c, A graph showing quantification of TUNEL + cells in hypertrophic zones of growth plates from n = 6 biologically independent animals. The data represent mean ± s.e.m. The P values were calculated using two-tailed unpaired t-tests. d, Left panels: confocal images showing the growth plates of three-week-old control and op/op mice from three independent litters. Emcn: red, vasculature; DAPI: blue, nuclei. Scale bars, 200 μm. Right: quantification of growth plate sizes from n = 5 control and n = 6 op/op animals confirms the unaltered size in osteopetrotic mutants. The data represent mean ± s.e.m. The P values were calculated using two-tailed unpaired t-tests with Welch's correction. e, Short-term alendronate treatment causes specific depletion of the VAO subset of osteoclasts. The images show osteoclasts (Itgb3, green) and blood vessel (Emcn, red) arrangements in control and alendronate-treated three-week-old mice. The white arrowheads in the images of the alendronate-treated bone sections indicate a few single (not anastomosing) bulge structures. Scale bars, 50 μm. The images are representative of three independent experiments. f, A graph showing quantification of anastomosing bulge structures in the vascular front of control and alendronate-treated bones from n = 9 biologically independent animals. The data represent mean ± s.e.m. The P values were calculated using two-tailed unpaired t-tests. g, Representative images showing osteoclast (Itgb3, green) distribution at the metaphysis of four-week-old mice subjected to short-term administration of liposome-encapsulated clodronate and the respective control mice, from three independent experiments. Scale bars, 50 μm. h, Left panels: tile scan images showing the growth plates of four-week-old mice treated with liposome-encapsulated clodronate and the respective control mice, from three independent experiments. Right panels: images showing blood vessel (Emcn, red) and osteoclast (Itgb3, green) staining at the disturbed epiphysis region compared to controls. The white arrowheads indicate a few uneven blood vessel invasions in the vascular front. Scale bars, 200 μm (left panel) and 50 μm (right panels).
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NATuRE CELL BIOLOGy bone/cartilage interface by mediating anastomoses of bulge structures in the vascular front. The number of bulges and their anastomoses decreases with age 16 , which supports the unaltered epiphysis line observed in long-term alendronate-treated bones.
Type H endothelium can digest cartilage matrix. The dispensable function of VAOs in cartilage resorption indicated the potential involvement of type H ECs in the phenotypes observed earlier (Fig. 3d,e and Supplementary Fig. 4) . iΔEC mutants and littermate controls from n = 6 biologically independent animals. The data represent mean ± s.e.m. The P values were calculated using two-tailed unpaired t-tests. e, Confocal images showing blood vessel arrangement (CD31, green) and osteoclast (Vpp3, magenta) distribution in Mmp9 iΔEC mutants and littermate controls from four independent experiments. Scale bars, 50 μm. f, A maximum-intensity projection of the tibial metaphysis of Mmp9 iΔOC mutants and their four-week-old littermate controls from four independent experiments. The images show that the distribution of osteoclasts is not affected in these osteoclast-specific mutants. Emcn: red, blood vessels; Itgb3: green, osteoclasts; DAPI: blue, nuclei. Scale bars, 50 μm. g, Tile scan confocal images illustrating the unaffected growth plate size in Mmp9 iΔOC mutants in comparison to their control littermates. Blood vessels were immunostained with endomucin (red). DAPI is a nuclei counterstain. Scale bar, 200 μm. The images are representative of three independent experiments. h, A graph showing quantification of growth plate sizes in Mmp9 iΔOC mutants and their littermate controls from n = 6 independent animals. The data represent mean ± s.e.m. The P values were calculated using two-tailed unpaired t-tests.
NATuRE CELL BIOLOGy leading structures in the epiphyseal bone growth (see blood vessels and VAO localizations in all control figures) corroborates the significance of these cells in resorbing cartilage matrix. Analysing osteoclast localization in the primary ossification centre of fetal long bones (Fig. 5a) Fig. 7 | Effect of misdirected blood vessels on bone shape. a, An experimental scheme illustrating the tamoxifen administration and alendronate treatment in Dll4 transgenic animals for misdirecting blood vessels to investigate their function in directional bone growth. i.p., intraperitoneal. b, A schematic illustration highlighting the behaviour of type H capillaries in each treatment condition that first misdirect and then promote blood vessel growth. c, Confocal tile scan images showing blood vessel (endomucin, Emcn, red) orientation in 10-week-old Dll4 iΔEC mutants and littermate control mice treated with alendronate in three independent experiments. DAPI stains nuclei. Note the growth plate (gp) size and the orientation of the bone in the treated conditions. The arrowheads in the right image of the alendronate-treated Dll4 iΔEC mutants indicate cartilage islands. Scale bars, 300 μm. d, Maximum-intensity projections of mouse tibial metaphysis immunostained for endomucin (red) to label blood capillaries. Dll4 iΔEC mutants show randomly oriented blood vessels in the metaphysis in comparison to their control littermates in three independent experiments. Alendronate treatment promoted growth of these randomly oriented blood vessels, leading to irregular resorption of growth plate cartilage. DAPI is a nuclear counterstain. Scale bars, 50 μm. e, Angle histogram plots showing the directional distribution of type H capillaries and chondrocytes relative to the proximal-distal axis of the tibia in Dll4 iΔEC mutants and littermate controls with alendronate administration.
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Timp1, Timp2, Timp3, Timp4, Mmp2, Mmp9, Mmp14, Adamts1 and Adamts5 were expressed at significantly higher levels in type H ECs relative to both the osteoclast subtypes (Fig. 5b) . Type H ECs displayed the highest fold expression (40-fold) for Mmp9 transcripts in comparison to VAOs and BAOs. Global deletion of the Mmp9 gene resulted in a defective growth plate with a large hypertrophic zone 32 , reminiscent of blood-vesselmediated defects. To analyse the endothelial-specific function of these proteinases in resorbing cartilage matrix, we generated a conditional Mmp9 transgenic mouse line to induce deletion in ECs or osteoclasts using Cdh5(PAC)-CreERT2 and Csf1r
Mer-iCre-Mer drivers, respectively. Following tamoxifen administration from P10 to P14, these transgenic animals were analysed on P28 to investigate resorption of growth plate cartilage. Targeting of Mmp9 in postnatal endothelium in bone (Mmp9 iΔEC ) led to the formation of large growth plates (Fig. 5c,d and Supplementary Fig. 6e ). These growth plates showed an increase in the number of apoptotic cells and both collagen-X and MMP13 expression (Fig. 5c and Supplementary Fig. 6f,g ) in the hypertrophic zone of mutants compared to littermate controls. No obvious change in blood vessel phenotype was observed in these mutants (Fig. 5e) . Conversely, inducible targeting of Mmp9 in postnatal osteoclasts (Mmp9 iΔOC ) did not lead to appreciable changes in osteoclasts number or in growth plate size compared to their littermate controls ( Fig. 5f-h and Supplementary Fig. 6g,h) . Thus, the above findings support the crucial role of EC-derived Mmp9 in invading cartilage matrix during bone formation.
Type H-mediated cartilage replacement mediates the directional elongation of bone. The elongation of an endochondral bone occurs at the growth plate. The growth rates and differential elongation rates of various skeletal elements are mainly structured by the longitudinal expansion of hypertrophic chondrocytes in the direction of growth within constraining matrix canals 1, 10, [33] [34] [35] [36] [37] . Remarkably, leading structures of type H capillaries were directed towards hypertrophic chondrocytes and seemed aligned with the matrix canals (Fig. 6a) . Quantification of angular orientations of blood vessels in bone sections established that type H capillaries were polarized towards chondrocytes and positioned along the axis of bone elongation. This directional growth of type H vessels towards the direction of bone elongation was observed not only in linear growth, but also in three-dimensional growth observed at secondary ossification centres (Fig. 6b-e and Supplementary  Fig. 6i ). These observations also correlated with the direction of elongation seen in other endochondral skeletal elements ( Supplementary Figs. 2a-d and 7a) . The cartilage-resorbing function and directional orientation of type H ECs intrigued us to question whether ECs provide directional cues during bone elongation. To investigate this, we redirected type H vessels to test whether elongation of long bone occurs at a different orientation. We combined Dll4 iΔEC mice with alendronate treatment to generate the growth of misdirected blood vessels and investigated directional bone growth in postnatal tibia. Endothelial Dll4 mutant bones show the formation of defective and irregular blood vessels during postnatal development 15 . Alendronate treatment promotes blood vessel growth 16 and simultaneously inhibits osteoclasts, a prerequisite condition required to investigate EC-specific functions in bone remodelling. Tamoxifen was administered from P35 to P39 to induce recombination, followed by alendronate treatments from P40 for 4 weeks on every alternate day (Fig. 7a) . Targeting Dll4 in postnatal endothelium (Dll4 iΔEC ) resulted in irregularly arranged type H vessels and increased growth plate size at P70. Combining this with alendronate administration promoted the growth of randomly directed blood vessels and led to the uneven invasion of the growth plate by blood vessels (Fig. 7b) . This in turn resulted in disproportionate removal of cartilage matrix in the growth plate leading to changes in bone shape. Remarkably, no proper growth plate was observed in these animals ( Fig. 7c-e) . Epiphyseal regions of these bones displayed cartilage islands, which potentially appeared as a result of the surrounding blood vessels (Supplementary Fig.  7b ). Thus, irregular invasion of the growth plate by blood vessels led to misdirected elongation of bone, displaying abnormal orientation (shape). However, the presence of osteoclasts, particularly VAO subsets, would promote anastomoses of newly formed blood vessels and inhibit this irregular invasion of cartilage. To test this, we promoted new blood vessel growth in Dll4 iΔEC mice without inhibiting osteoclasts by intermittent parathyroid hormone (PTH; 100 μg kg −1 wild-type (WT) mice) administration. Intermittent PTH increases bone blood flow 38, 39 and was shown to not affect osteoclast activity 40 . Remarkably, PTH-mediated growth of new blood vessels in Dll4 iΔEC mice displayed limited elongation into the cartilage matrix. The formation of new type H vessels in these animals was associated with the revival of the VAO subset, which in turn promoted anastomoses of type H capillaries. This resulted in limited invasion of cartilage and no change in bone orientation was observed ( Supplementary Fig. 7c-f) . In addition to establishing the role of blood vessels in directing bone elongation, this finding also suggested the supportive role played by VAOs in assisting the blood vessel growth.
Discussion
The cellular and molecular mechanisms involved in directing the individual bones to acquire their characteristic shapes during endochondral ossification are poorly understood. The elongation of endochondral bones at the growth plate involves continuous replacement of cartilage matrix by calcified bone to achieve their typical shapes. In addition to developmental bone formation, cartilage resorption is an important mechanism during the repair process after fracture or injury 3, 41, 42 . Pathological conditions such as arthritis 43, 44 and cancer involve unregulated removal of cartilage matrix and bone formation [45] [46] [47] [48] . The cellular composition, organization and regulation of the bone/cartilage interface mediating the replacement of cartilage and directional elongation of skeletal elements are long-standing fundamental questions in skeletal physiology.
In this study, we identified and classified osteoclast subtypes on the basis of their structures and localization-VAOs and BAOs. While BAOs are classical osteoclasts, VAOs regulate blood vessel growth in bone. RNA-seq data demonstrated distinct expression profiles for VAOs and BAOs. Furthermore, characterization of VAOs also established that VAO subsets are different from previously recognized pre-osteoclast and macrophage populations 49, 50 . The prevalence of VAO during bone formation and BAO in bone loss provides a fundamental approach to consider both the subtypes to understand the resorption status of bone. Investigating osteoclast subtypes in developmental bone diseases will provide additional perspectives to understand the pathological conditions better and develop effective therapeutic strategies.
Despite blood vessels being identified as an important component of endochondral bone growth, their role in the removal of cartilage matrix has not been recognized. Inhibiting blood vessel growth results in enlarged growth plate size due to the defective cartilage resorption. This matrix-digesting function of endothelium is supported by the enlarged growth plate phenotype observed in a number of studies that affected angiogenic growth of blood vessels in bone 11, 15, 51 . This finding is particularly important to understand the pathology of conditions associated with tissue degeneration and damage as observed in osteoarthritis, ageing, fracture repair and cancer. Together, our findings illustrate a function of ECs in skeletal matrix resorption, which provides the framework for understanding differential elongation of various skeletal elements and for investigating skeletal pathologies.
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Methods
Ethical review. All animal experiments were performed in compliance with the relevant laws and institutional guidelines and were approved by local animal ethics committees.
WT and genetically modified mice. All WT bones were obtained from C57BL/6J mice from the specified age groups as mentioned in the text. For experiments involving WT mice, male mice were generally used, whereas in experiments involving transgenic animals, both male and females were used.
For lineage tracing experiments, Csf1r
Mer-iCre-Mer mice 17 were bred with the Rosa26-tdTomato reporter transgenic mouse line 18 . To induce Cre activity, tamoxifen (Sigma, T5648) was injected intraperitoneally at a dose of 12 mg kg 
Cdh5(PAC)-CreERT2
T/+ (Vhl iΔEC ) mutant mice were used for the study. A two-time injection schedule with five injections in each schedule was followed to induce gene deletion in aged mice. Each schedule involved the injection of 1,000 μg tamoxifen (Sigma, T5648) intraperitoneally every day for 5 days. Before the second schedule, the mice were rested for 16 days. The mice were again rested for 16 days after the second schedule before being euthanized to collect femurs and tibiae for analysis.
Mice carrying the osteopetrosis mutation (op/op) were purchased from Jackson Laboratory (stock; 000231) for analysis. Homozygous animals showed impaired dental growth and a domed skull.
For Vegfr2 inhibitor treatment, SU5416 (Sigma, S8442) was administered intraperitoneally at a 25 mg kg −1 dose 5 times from P10 and analyses were carried out at P28.
Control fluorescent DiI liposome and liposome clodronate suspensions were purchased from Liposoma. The homogeneous suspensions in PBS (5 mg ml −1 ) were mixed well before injecting into animals. For labelling macrophages, 100 μl control fluorescent DiI liposome was injected intravenously and observations were carried out after 6, 24, 48 and 72 h. For depletion of VAOs, liposome clodronate was injected 3 times intravenously at 48 h intervals and analyses were performed 7 days after the first injection.
All animal experiments were performed in compliance with the local ethical and care guidelines at the Imperial College London and the International Guidelines of the Home Office (UK).
Immunohistochemistry staining and analysis. Tibiae were collected by dissection from WT mice or mutant and control littermates and fixed immediately in 4% paraformaldehyde solution for 4 h on ice. Bones were decalcified with 0.5 M EDTA with constant shaking at 4 °C. Following decalcification, bones were kept for 24 h in 20% (w/v) sucrose and 2% (w/v) polyvinylpyrrolidine solution. Before cryosectioning, bones were embedded in 8% (w/v) gelatin, 20% (w/v) sucrose and 2% polyvinylpyrrolidine. Bone sections were generated using a Leica 3050S cryostat on microscopic slides and allowed to air-dry. The detailed protocol was published earlier 55 . For immunostaining and phenotypic analyses, bone sections were hydrated, permeabilized with 0.25% Triton-X for 10 min, blocked with 5% donkey serum (blocking solution) for 30 min and incubated with primary antibodies diluted in blocking solution for 2.5 h at room temperature or overnight at 4 °C. Primary antibodies used: endomucin (Santa Cruz, 1:100), tartate-resistant alkaline phosphatase (TRAP; Thermo Scientific, 1:100), integrin beta 3 (Cell Signaling, Following primary antibody staining, the slides were washed with PBS, 3 times, 5 min each and incubated with the relevant Alexa Fluor-conjugated secondary antibodies for 1 h at room temperature. Secondary antibodies used: anti-rat Alexa Fluor 594 (Invitrogen; A21209, 1:400), anti-rabbit Alexa Fluor 546 (Invitrogen; A11035, 1:400), anti-goat Alexa Fluor 488 (Invitrogen; A11055, 1:400), anti-goat Alexa Fluor 647 (Invitrogen; A21447, 1:400) and DAPI for nuclear staining. Sections were washed with PBS thoroughly and then mounted with FluoroMount-G solution (Southern Biotech) and sealed with coverslips.
High-resolution immunofluorescent images were acquired using a Leica TCS SP8 confocal laser scanning microscope.
TUNEL assay. Bones were processed as above and 25 μm sections were generated using the cryostat. TUNEL (Sigma-Aldrich 11767305001) assay was performed as per the manufacturer's guidelines. Briefly, TUNEL labelling was performed after the immunostaining protocol. The reaction mixture was prepared by mixing 5 μl TUNEL enzyme with 45 μl TUNEL label buffer per sample and incubated for 60 min at 37 o C in a humidified chamber in the dark. The slides were washed three times with PBS, mounted and imaged using a Leica SP8 confocal laser scanning microscope.
EdU labelling. For EdU labelling of proliferating cells, we injected mice with 300 μg EdU (Invitrogen) intraperitoneally and euthanized them 3 h after the injection. Bones were collected immediately and processed following the protocol described earlier. The bone cryosections were immunostained for EdU using Click-iT chemistry following the manufacturer's protocols (Invitrogen).
Flow cytometry. C57Bl/6 WT mice were used for isolating osteoclasts. We generally collected bones from both femurs and tibiae of two or more animals. Bones were dissected and cleaned of all adhering muscle and crushed with a mortar and pestle in ice-cold PBS. Red blood cell lysis was performed on total bone marrow cells to deplete erythrocytes. Further collagenase digestion was performed for 30 min at 37 °C. Cells were then washed and filtered to obtain a single-cell suspension.
Cells were stained with anti-RANK-PE (Invitrogen 1:50) for 1 h on ice followed by labelling with Vybrant Dye Cycle (Thermofisher Scientific) for 30 min at 37 °C. Cells were either analysed using LSR II or sorted using Aria III (BD Biosciences) with FACSDiva software. Total RANK + cells were gated for separating the cells further on the basis of their nuclear content using Vybrant dye. In general, we sorted two-nucleated cells for VAO and four (or more)-nucleated cells for the BAO subset.
CD31 and endomucin FACS immunostaining was performed following the protocol published earlier 14 .
Irradiation and transplantation assay. For irradiation experiments, 8-week-old WT C57BL/6J mice were sub-lethally irradiated at 650 rad. The double-transgenic Csf1r Mer-iCre-Mer with Rosa26-tdTomato reporter mouse line was used for labelling cells. Sorted Tomato + VAO and BAO subsets of purified 5 × 10 4 osteoclasts were transplanted intravenously into irradiated mice along with WT bone marrow cells. Transplanted mice were euthanized after seven days and bones were analysed for the presence of Tomato + cells. The BAO subset did not survive transplantation as Tomato + cells were not observed in the transplanted mice.
Quantitative PCR with reverse transcription. Cells were sorted directly into lysis buffer of the RNeasy Plus Micro Kit (QIAGEN). Total RNA was isolated as per the manufacturer's guidelines. One hundred nanograms of DNA/reaction was used for complementary DNA synthesis using the iScript cDNA Synthesis System (Bio-Rad). Quantitative PCR was performed using PowerUp SYBR Green RealTime PCR Master Mix with customized primer pairs. The sequences of the primer pairs used in the study can be provided on request. All gene expression assays were normalized to endogenous Actb levels.
Image processing and quantification. Z-stacks of images were threedimensionally reconstructed and analysed using Imaris Image Analysis Software (version 9.0). ImageJ, Adobe Illustrator and Adobe Photoshop were used to process images in compliance with the Nature's publication guidelines for processing digital images. IMARIS and ImageJ were used for all quantifications.
Quantification of osteoclasts. The numbers of osteoclasts were manually quantified on high-resolution images using IMARIS and ImageJ software. Mono-or bi-nucleated osteoclast structures present in close association with blood vessels were considered as VAOs and large multinucleated (with more than four nuclei) cells present on the bone surface were considered as BAOs. For quantifying the number of nuclei, high-resolution z-stack images of osteoclasts were visualized at multiple planes to count the number of nuclear structures in the cell. Similarly, the sizes of osteoclasts were measured along the length of their interaction with either blood vessels or bone. Last updated by author(s): Nov 12, 2018 Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
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